Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Teva
Baxter
US Army
QuintilesIMS
Healthtrust
Federal Trade Commission
AstraZeneca

Generated: November 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BROMOCRIPTINE MESYLATE

« Back to Dashboard

Clinical Trials for Bromocriptine Mesylate

Trial ID Title Status Sponsor Phase Summary
NCT00377676 Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes Completed VeroScience Phase 3 Cycloset, a new quick-release oral formulation of bromocriptine mesylate, effectively reduces blood sugar by the proposed mechanism of reversing many of the metabolic alterations associated with insulin resistance and obesity by resetting central (hypothalamic) circadian organization of monoamine neuronal activities. The primary analysis of this study will test the hypothesis that the rate of all-cause severe adverse events for those receiving usual drug therapy for diabetes management plus Cycloset is not greater than that for usual drug therapy plus placebo by more than an acceptable margin. While the primary purpose of this study is to establish the safety profile of Cycloset in type 2 diabetes, any potential positive cardiovascular benefits will be evaluated as well.
NCT00649168 Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg Completed Mylan Pharmaceuticals Phase 1 The objective of this study was to assess the single-dose relative bioavailability of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 5 mg bromocriptine mesylate capsules, following the administration of a 10 mg dose, under fed conditions.
NCT00650520 Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets Completed Mylan Pharmaceuticals Phase 1 The objective of this study is to assess the single-dose relative bioavailability of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg bromocriptine mesylate tablets, following the administration of a 10 mg dose, under fed conditions.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Bromocriptine Mesylate

Condition Name

Condition Name for Bromocriptine Mesylate
Intervention Trials
Healthy 2
Type 2 Diabetes Mellitus 1
Type 2 Diabetes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Bromocriptine Mesylate
Intervention Trials
Diabetes Mellitus 2
Diabetes Mellitus, Type 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Bromocriptine Mesylate

Trials by Country

Trials by Country for Bromocriptine Mesylate
Location Trials
United States 5
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Bromocriptine Mesylate
Location Trials
Connecticut 1
Arizona 1
Pennsylvania 1
Missouri 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Bromocriptine Mesylate

Clinical Trial Phase

Clinical Trial Phase for Bromocriptine Mesylate
Clinical Trial Phase Trials
Phase 3 1
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Bromocriptine Mesylate
Clinical Trial Phase Trials
Completed 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Bromocriptine Mesylate

Sponsor Name

Sponsor Name for Bromocriptine Mesylate
Sponsor Trials
Mylan Pharmaceuticals 2
VeroScience 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Bromocriptine Mesylate
Sponsor Trials
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
US Army
McKinsey
Teva
Chubb
Cipla
Daiichi Sankyo
Deloitte
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.